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Abstract
Introduction: Splenic tumors are rare and present a diagnostic dilemma. Metastatic carcinoma to the spleen is
unusual. Visceral metastases in patients with ovarian cancer represent hematogenous spread of the disease;
capsular involvement resulting from serosal and peritoneal seeding is more common. We present a patient with
intraparenchymal splenic metastasis from ovarian carcinoma. This case demonstrates a rare etiology of an
intraparenchymal solid splenic mass.
Case presentation: An 85-year-old woman presented with left upper quadrant pain. During her evaluation, a
computed tomography scan revealed intraparenchymal splenic masses. An elective splenectomy was performed,
during which ovarian cancer, which had not been revealed by the pre-operative computed tomography, was
detected. There was no involvement of the splenic capsule by direct extension of the tumor, as is usually the case
for ovarian cancer, but only intraparenchymal metastases. This mode of metastasis to the spleen has been
described but is quite rare, and ovarian cancer presenting as a splenic mass is even more so.
Conclusion: Splenic metastasis is a relatively rare event. It is often asymptomatic and is usually detected as part of
multiorgan metastases. Symptomatic cases, though rare, do occur, and as in our patient, a thorough clinical
evaluation is important to help direct the treatment plan. This case is a reminder to be cognizant of one of the
less likely differential diagnoses of an intraparenchymal solid splenic mass.
Introduction
Splenic tumors are rare and present a diagnostic
dilemma. The differential diagnosis of splenic tumors
includes hemangioma, lymphangioma, hamartoma,
hemangiosarcoma, malignant lymphoma, and metastatic
carcinoma.
Metastatic carcinoma to the spleen is unusual. Visc-
eral metastases in patients with ovarian cancer represent
hematogenous spread of the disease, and are present in
2% to 3% of patients [1]. Capsular involvement resulting
from serosal and peritoneal seeding is much more com-
mon [2]. A review of the literature reveals that about
half of reported splenectomies for ovarian cancer were
performed at the time of primary cytoreduction, and the
other half were done at secondary debulking. The large
majority of these did not have parenchymal splenic
involvement [3].
We present a rare case of intraparenchymal splenic
metastasis from ovarian carcinoma.
Case presentation
An 85-year-old woman originally presented to her pri-
mary care physician with vague pain in her left upper
quadrant. She described it as a sharp, intermittent pain,
not associated with meals. The pain was exacerbated by
different body positions and by activity. She experienced
loss of appetite and five pounds of weight loss. She had
no significant past medical history, but had recently had
both upper and lower endoscopies, which were normal.
Physical exam revealed tenderness in her left upper
quadrant. No organomegaly was identified, and no other
tenderness or palpable masses were present on examina-
tion. A computed tomography (CT) scan of her abdo-
men was ordered by her primary care physician, and
this showed multiple masses within the spleen which
were suspicious for malignancy (Figure 1). Because of
the CT findings and the patient’s complaint of pain, she
was referred for splenectomy.
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lytes were within normal limits. A laparoscopic splenect-
omy was initiated but due to extensive adhesions and
multiple tumor implants, the procedure was converted
to an open approach. On exploration, numerous omen-
tal, mesenteric, peritoneal, and diaphragmatic implants
were identified. The splenic capsule, however, appeared
to be uninvolved. A splenectomy, omentectomy, removal
of peritoneal nodules, and right oophorectomy were per-
formed. The left ovary was not identifiable due to the
dense adhesions and implants matted in that area.
Pathologic examination of the gross specimen (Figure
2) revealed intraparenchymal splenic lesions. Represen-
tative sections from the ovary (Figure 3) and spleen (Fig-
ure 4) are shown here. The tumor at both sites showed
a similar morphology of a poorly differentiated adeno-
carcinoma consisting of irregular nests of large anaplas-
tic polygonal cells with an ill-defined cribriform pattern
(Figure 3, inset). The ovary was almost completely
replaced by tumor. There were multiple splenic nodules
showing invasive growth. Special stains (not shown)
were identical between the sites, with small amounts of
intracytoplasmic mucin on mucicarmine stain. Neoplas-
tic cells showed positive immunohistochemical staining
for pankeratin, estrogen receptor, and CK7 and were
negative for progesterone receptor, carcinoembryonic
antigen (CEA), and CK20 in sections from both sites
(not shown). This immunophenotype is indicative of a
primary ovarian adenocarcinoma.
A CA-125 level checked postoperatively was markedly
elevated at 685.9 units/mL (normal: <35 units/mL). The
patient made an uneventful postoperative recovery, and
was discharged home. After a consultation with oncol-
ogy, she is currently undergoing chemotherapy.
Discussion
Metastatic carcinoma to the spleen is rare [1,3]. The
incidence of splenic metastasis among patients with
solid tumors has been reported to vary from 9% to 16%
[4]. There appears to be no difference in incidence
between men and women, but it is more frequently
found in the elderly [5]. Cancers of the lung, breast,
skin, ovary, colon, and stomach are the most common
primary sites, with lung being the most frequent [6]. In
most cases, the spleen is involved as part of a diffuse
carcinomatosis [3], and splenic metastasis reflects wide-
spread tumor dissemination. Warren and Davis reported
that the incidence of metastases to the spleen ranged
from 0.3% to 4.8%, based on autopsy reports. The pau-
city of afferent lymphatics to the splenic parenchyma
and the motility of the organ might explain why it is a
rare site of metastasis [7]. Other proposed explanations
have included: the sharp angle made by the splenic
artery, which makes it difficult for tumor emboli to
enter the spleen; the rhythmic contractile nature of the
spleen, which may squeeze out the tumor emboli; and
antitumor activity due to a high concentration of lym-
phoid tissue in the spleen [5].
Lam and Tang conducted a 25-year-long clinicopatho-
logic study where they concluded that metastatic disease
involving the spleen may not be readily identified for
several reasons. First, many splenic metastases are
asymptomatic, making their detection more difficult.
Symptomatic lesions tend to be larger, and thus are
more likely to be part of a more widely metastatic
tumor. Also, some patients in the study had splenic
lesions that were so small that they could not be easily
identified on gross examination during an abdominal
exploration. Lastly, many of the grossly detectable
lesions were solitary or diffuse rather than multiple,
Figure 1 Computed tomography scan showing splenic masses.
Figure 2 Sections of spleen showing intraparenchymal masses.
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splenic tumors such as lymphomas or hamartomas [5].
The location of the primary tumor appears to affect
the frequency of metastases to the spleen. For example,
one series found that pancreatic primary tumors metas-
tasized to the spleen more often than to other primary
sites [5]. The proximity of the primary and the direct
vascular access of the splenic artery and vein doubtless
contributed to this finding. It has also been noted that
types of tumors with a high mortality rate and high inci-
dence within a given population are more likely to be
the primary tumor in a patient with newly discovered
splenic metastasis.
Late metastases to the spleen are seen more often in
melanomas, choriocarcinomas, and breast carcinomas.
Symptomatic lesions, when compared to asymptomatic
lesions, were larger and were found more often in
women and younger patients [5]. Those asymptomatic
lesions that have been reported have been associated
with splenic rupture [8]. Spl e n i cr u p t u r ea sap r e s e n t a -
tion of metastatic disease has been described, but is very
rare [5]. In our patient, the splenic lesions were large
and were easily seen on CT scan, and were probably
contributing to the patient’s left upper quadrant pain.
Metastases to the spleen are frequently found as part
of a widely metastatic primary tumor. In one study, all
patients found to have metastatic splenic tumors even-
tually died of complications of their primary tumors [5].
Splenectomy has been performed for metastatic disease
for tissue diagnosis and for prevention of eventual sple-
nic rupture. However, it has been proposed that routine
resection of the primary tumor may not be justified
based on the likely widespread nature of the tumor and
high associated mortality rate [9].
Involvement of the splenic capsule in epithelial ovar-
ian cancer usually occurs with widespread tumor disse-
mination [3], and is not as rare as metastatic
parenchymal splenic involvement. Autopsy studies have
revealed that splenic capsular involvement occurred in
19% to 52% of cases of epithelial ovarian cancer [10]. In
most of these reports, the spleen was involved as part of
diffuse carcinomatosis, and there are only a few cases of
isolated parenchymal metastases [1,11,12]. More com-
mon primary tumor sites of splenic metastases are lung,
breast, and skin affected with melanoma [13].
Pathology from our case revealed metastatic poorly
differentiated adenocarcinoma from the splenic lesions
and poorly differentiated papillary mucinous cystadeno-
carcinoma from the right ovary. There were several par-
enchymal metastases in the spleen, and intra-abdominal
dissemination of the tumor. The capsule of the spleen
in our patient was not involved by direct invasion. Par-
enchymal metastases may represent hematogenous
spread of the disease, whereas capsular involvement
represents peritoneal seeding [14].
Solitary splenic metastasis of carcinoma of ovarian ori-
gin is exceedingly rare, with fewer than 25 reported
cases. Splenic involvement, even parenchymal involve-
ment excluding direct invasion into the capsule, is
usually associated with widespread intra-abdominal dis-
semination of the tumor. This, in fact, was the case with
our patient, who had widespread visceral, peritoneal,
and diaphragmatic tumor implants. In the rare cases of
solitary splenic metastasis, splenectomy may have value
beyond providing tissue diagnosis and preventing splenic
Figure 3 Representative section of ovary stained with
hematoxylin and eosin (100×) demonstrating irregular nests of
large anaplastic cells with an ill-defined cribriform architecture
infiltrating the ovary. No residual normal ovarian tissue is shown.
Figure 4 Representative section of spleen stained with
hematoxylin and eosin (20×) demonstrating morphology
similar to that seen in the ovary. Normal residual spleen is seen
on the right.
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and an appropriate chemotherapy regimen, can be part
of a therapeutic and not merely a palliative procedure.
Laparoscopic splenectomy, if achievable, is preferred
over open splenectomy in these cases [2].
Our patient had multiple parenchymal splenic metas-
tases and was symptomatic. In fact, her initial presenta-
tion was because of the discomfort caused by her
affected spleen. She had an elevated CA-125 level and
there were visible parenchymal splenic lesions on CT
imaging. Splenectomy, omentectomy, removal of perito-
neal nodules, and a right oophorectomy were per-
formed. In reported cases, an open surgical splenectomy
was performed except in two patients where a laparo-
scopic approach was used [2,3]. The advantages of
laparoscopic splenectomy over an open approach
include a shortened in-patient stay and a quicker recov-
ery time. In general, patients who underwent a laparo-
scopic splenectomy can be started on a chemotherapy
regimen sooner than those with an open splenectomy,
which might favorably affect their outcome [2,13,15].
Conclusion
In conclusion, splenic metastasis is a relatively rare
event. It is often asymptomatic and is usually detected
as part of multiorgan metastases [5]. Symptomatic cases,
though rare, do occur, and as in our patient, a thorough
clinical evaluation was important to help initiate the
proper workup. This case is a reminder to be cognizant
of one of the less likely differential diagnoses of an
intraparenchymal solid splenic mass.
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